Lower-dose radiation safe for certain lower-risk, HPV-positive head and neck cancers

Regorafenib shows early promise in colorectal candidates unable to undergo chemo

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia

Phase III SELECT trial shows lenvatinib to be effective in resistant thyroid cancer

Genomic sequencing helps identify best candidates for adjuvant chemo in colorectal cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

First-line bevacizumab plus chemo and cetuximab plus chemo provide similar survival benefits in metastatic colorectal cancer

First-line bevacizumab plus chemotherapy and cetuximab plus chemotherapy provide similar survival benefit for patients with metastatic colorectal cancer

Addition of docetaxel to initial hormone therapy substantially improves survival in metastatic, hormone-sensitive prostate cancer

Comment: Advances in lung cancer presented at ASCO 2014

Comment: Advances in breast cancer presented at ASCO 2014

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC